Cardiome Pharma Corp., a specialty pharmaceutical company, announced that an affiliate of the company has entered into an agreement with Pharmacare Limited, which trades as Aspen Pharmacare and is a part of the Aspen Group, to sell and distribute Brinavess (vernakalant intravenous) exclusively in South Africa.
Under the terms of the agreement, Aspen has agreed to specific annual commercial goals for Brinavess. Financial details of the agreement have not been disclosed.
“We are pleased to expand our commercial agreement with Aspen to now include Brinavess in South Africa,” said Karim Lalji, Cardiome’s chief commercial officer. “Aspen has proven to be a valuable partner to Cardiome through their commercialization efforts behind Aggrastat. This will be the first country in Africa where Brinavess will be launched and we remain committed to making this drug available to all our customers worldwide.”
“It is exciting for us to expand our portfolio to now include Brinavess alongside Cardiome’s Aggrastat,” said Noel Guliwe, CEO at Aspen Pharmacare, South Africa. “We are looking forward to making it available to all of our hospital customers throughout the country.”
Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.
Aspen is a global supplier of branded and generic pharmaceutical products as well as infant milk nutritionals and consumer healthcare products in selected territories.